[德国儿童荨麻疹的护理和医疗费用:药物、医疗和住院服务]。

Dermatologie (Heidelberg, Germany) Pub Date : 2024-07-01 Epub Date: 2024-05-22 DOI:10.1007/s00105-024-05346-3
Petra Staubach, Caroline Mann, Kristina Hagenström, Matthias Augustin
{"title":"[德国儿童荨麻疹的护理和医疗费用:药物、医疗和住院服务]。","authors":"Petra Staubach, Caroline Mann, Kristina Hagenström, Matthias Augustin","doi":"10.1007/s00105-024-05346-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Data on the course of urticaria in children exist, but there is a lack of sound data on patient management to ensure high-quality care.</p><p><strong>Methods: </strong>Retrospective secondary data analysis in the field of health care and epidemiology in children with urticaria based on routine data from a German health insurance company (DAK-Gesundheit). Data from insured persons under 18 years of age who were treated as outpatients or inpatients with a diagnosis of urticaria (according to ICD-10 classification) in 2010-2015 were included. The control group consisted of children without a corresponding diagnosis, in order to clarify health economic and care-related differences after adjusting for age and gender.</p><p><strong>Results: </strong>In 2015, 1904 (1.3%) of 151,248 insured minors had a diagnosis of urticaria. Of the children with urticaria, 70.9% visited at least one physician on an outpatient basis. Of these visits, 70.9% were made to a pediatrician, 52.5% to a general practitioner and 33.0% to a dermatologist; 11% were treated as inpatients. With a total of 151,248 insured persons, 1904 of whom were diagnosed with urticaria, 72.9% of children and adolescents with versus 28.9% without urticaria were treated topically or systemically in 2015, including 10.5% of children with urticaria vs. 2.6% without urticaria received topical therapy and 70.0% with urticaria received systemic therapy vs. 27.5% without urticaria with systemic therapy. The most commonly used oral medications for urticaria were cetirizine (44.2%), prednisolone (9.8%), and dimetindene (2.0%) . Topical methylprednisolone aceponate (49.8%) was prescribed most frequently. The therapy costs for systemic drugs was € 24.00 per patient, while topical drugs cost € 1.58 per patient.</p><p><strong>Conclusion: </strong>The lack of guidelines for the standardization of treatment in children still leads to ambiguities and different treatment concepts among the specialist groups, which must be eliminated in order to enable more efficient therapies. The treatment of chronic urticaria in children and adolescents is mainly carried out by pediatricians, general practitioners and dermatologists. Systemic and topical medications as well as inpatient services are the most important cost factors.</p>","PeriodicalId":72786,"journal":{"name":"Dermatologie (Heidelberg, Germany)","volume":" ","pages":"554-561"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11224104/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Care and medical costs of urticaria in children in Germany : Drugs, medical and inpatient services].\",\"authors\":\"Petra Staubach, Caroline Mann, Kristina Hagenström, Matthias Augustin\",\"doi\":\"10.1007/s00105-024-05346-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Data on the course of urticaria in children exist, but there is a lack of sound data on patient management to ensure high-quality care.</p><p><strong>Methods: </strong>Retrospective secondary data analysis in the field of health care and epidemiology in children with urticaria based on routine data from a German health insurance company (DAK-Gesundheit). Data from insured persons under 18 years of age who were treated as outpatients or inpatients with a diagnosis of urticaria (according to ICD-10 classification) in 2010-2015 were included. The control group consisted of children without a corresponding diagnosis, in order to clarify health economic and care-related differences after adjusting for age and gender.</p><p><strong>Results: </strong>In 2015, 1904 (1.3%) of 151,248 insured minors had a diagnosis of urticaria. Of the children with urticaria, 70.9% visited at least one physician on an outpatient basis. Of these visits, 70.9% were made to a pediatrician, 52.5% to a general practitioner and 33.0% to a dermatologist; 11% were treated as inpatients. With a total of 151,248 insured persons, 1904 of whom were diagnosed with urticaria, 72.9% of children and adolescents with versus 28.9% without urticaria were treated topically or systemically in 2015, including 10.5% of children with urticaria vs. 2.6% without urticaria received topical therapy and 70.0% with urticaria received systemic therapy vs. 27.5% without urticaria with systemic therapy. The most commonly used oral medications for urticaria were cetirizine (44.2%), prednisolone (9.8%), and dimetindene (2.0%) . Topical methylprednisolone aceponate (49.8%) was prescribed most frequently. The therapy costs for systemic drugs was € 24.00 per patient, while topical drugs cost € 1.58 per patient.</p><p><strong>Conclusion: </strong>The lack of guidelines for the standardization of treatment in children still leads to ambiguities and different treatment concepts among the specialist groups, which must be eliminated in order to enable more efficient therapies. The treatment of chronic urticaria in children and adolescents is mainly carried out by pediatricians, general practitioners and dermatologists. Systemic and topical medications as well as inpatient services are the most important cost factors.</p>\",\"PeriodicalId\":72786,\"journal\":{\"name\":\"Dermatologie (Heidelberg, Germany)\",\"volume\":\" \",\"pages\":\"554-561\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11224104/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologie (Heidelberg, Germany)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00105-024-05346-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologie (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00105-024-05346-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:有关儿童荨麻疹病程的数据是存在的,但缺乏有关患者管理的可靠数据,因此无法确保高质量的医疗服务:方法:根据德国医疗保险公司(DAK-Gesundheit)的常规数据,对儿童荨麻疹患者的医疗保健和流行病学领域进行回顾性二手数据分析。研究纳入了 2010-2015 年期间因诊断为荨麻疹(根据 ICD-10 分类)而接受门诊或住院治疗的 18 岁以下投保人的数据。对照组由没有相应诊断的儿童组成,以便在对年龄和性别进行调整后明确健康经济和护理相关的差异:2015年,151248名参保未成年人中有1904人(1.3%)被诊断为荨麻疹。在患有荨麻疹的儿童中,70.9%的儿童至少在门诊看了一位医生。其中,儿科医生占 70.9%,全科医生占 52.5%,皮肤科医生占 33.0%;住院病人占 11%。2015年,共有151248名投保人,其中1904人被诊断患有荨麻疹,72.9%患有荨麻疹的儿童和青少年与28.9%未患荨麻疹的儿童和青少年接受了局部或全身治疗,其中10.5%患有荨麻疹的儿童与2.6%未患荨麻疹的儿童接受了局部治疗,70.0%患有荨麻疹的儿童与27.5%未患荨麻疹的儿童接受了全身治疗。最常用的荨麻疹口服药物是西替利嗪(44.2%)、泼尼松龙(9.8%)和地美茚(2.0%)。最常用的外用药是醋酸甲泼尼龙(49.8%)。全身用药的治疗费用为每位患者 24.00 欧元,而局部用药的治疗费用为每位患者 1.58 欧元:结论:由于缺乏儿童治疗标准化指南,专家小组之间的治疗概念仍然模糊不清,治疗方法也不尽相同,为了提高治疗效率,必须消除这些问题。儿童和青少年慢性荨麻疹的治疗主要由儿科医生、全科医生和皮肤科医生负责。全身和局部用药以及住院服务是最重要的成本因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Care and medical costs of urticaria in children in Germany : Drugs, medical and inpatient services].

Background: Data on the course of urticaria in children exist, but there is a lack of sound data on patient management to ensure high-quality care.

Methods: Retrospective secondary data analysis in the field of health care and epidemiology in children with urticaria based on routine data from a German health insurance company (DAK-Gesundheit). Data from insured persons under 18 years of age who were treated as outpatients or inpatients with a diagnosis of urticaria (according to ICD-10 classification) in 2010-2015 were included. The control group consisted of children without a corresponding diagnosis, in order to clarify health economic and care-related differences after adjusting for age and gender.

Results: In 2015, 1904 (1.3%) of 151,248 insured minors had a diagnosis of urticaria. Of the children with urticaria, 70.9% visited at least one physician on an outpatient basis. Of these visits, 70.9% were made to a pediatrician, 52.5% to a general practitioner and 33.0% to a dermatologist; 11% were treated as inpatients. With a total of 151,248 insured persons, 1904 of whom were diagnosed with urticaria, 72.9% of children and adolescents with versus 28.9% without urticaria were treated topically or systemically in 2015, including 10.5% of children with urticaria vs. 2.6% without urticaria received topical therapy and 70.0% with urticaria received systemic therapy vs. 27.5% without urticaria with systemic therapy. The most commonly used oral medications for urticaria were cetirizine (44.2%), prednisolone (9.8%), and dimetindene (2.0%) . Topical methylprednisolone aceponate (49.8%) was prescribed most frequently. The therapy costs for systemic drugs was € 24.00 per patient, while topical drugs cost € 1.58 per patient.

Conclusion: The lack of guidelines for the standardization of treatment in children still leads to ambiguities and different treatment concepts among the specialist groups, which must be eliminated in order to enable more efficient therapies. The treatment of chronic urticaria in children and adolescents is mainly carried out by pediatricians, general practitioners and dermatologists. Systemic and topical medications as well as inpatient services are the most important cost factors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Skin aging and dermatoporosis-the chronic skin fragility syndrome]. [Disseminated pyoderma gangrenosum in ulcerative colitis]. [Onychopapilloma : Diagnosis and surgical treatment of a rare nail tumor]. [Skin fragility in autoimmune blistering diseases of the skin]. [Erythema nodosum].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1